Novo Nordisk shares down on report of potential Ozempic price cuts

September 18, 2024 07:47 PM AEST | By Investing

Google News:

Novo Nordisk shares down on report of potential Ozempic price cuts

Recent News

Morgan Stanley downgrades Lululemon on weak US growth outlook

Canada to hit NATO defense target early - The Globe and Mail

Qualcomm at 40: Here’s How We Drove Five of the Biggest Tech Revolutio...

Mastercard Economics Institute: Circular Fashion Is Sew on Trend

Investing.com -- Shares of Novo Nordisk (NYSE:NVO) A/S fell on Wednesday after Bloomberg reported that Ozempic, Novo Nordisk’s diabetes drug, is ”very likely” to be one of the next drugs targeted for a price cut in bargaining with the US government’s Medicare program.

At 4:55 am (0855 GMT), Novo Nordisk was trading 1.7% lower at DKK 888.4.

This comes after the Inflation Reduction Act, which empowers the U.S. government to negotiate drug prices with manufacturers, potentially leading to significant reductions in costs. Ozempic, currently approved for treating diabetes but widely used for
weight loss, has become a key revenue driver for Novo Nordisk.

The drug’s U.S. list price is $968.52 per month, and it is covered by most Medicare plans for type 2 diabetes.

Ulrich Otte, Novo Nordisk's senior vice president of finance&operations, confirmed at the Cantor Global Healthcare Conference in New York that it is "very likely" Ozempic will be part of the next round of Medicare price negotiations.

Otte stated that the company is preparing for this possibility but warned that dramatic price cuts could impact the industry's capacity for innovation.

The U.S. Centers for Medicare and Medicaid Services (CMS) is expected to release the list of 15 drugs targeted for the next round of negotiations by early 2025, with new pricing set to take effect in 2027.

Novo Nordisk CEO Lars Fruergaard Jørgensen is also slated to testify before a Senate committee next week, as political pressure grows over the high costs of life-saving medications in the U.S, the report added.

Otte’s statement comes amid broader market concerns over the impact of the Inflation Reduction Act, which recently slashed prices for 10 major medications by 38% to 79%, effective in 2026.

This article first appeared in Investing.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.